Human Anti-EGFR Recombinant Antibody (clone E7.6.3) (CAT#: HPAB-S0022-YC)

Figure 1 The inhibition of EGF binding to EGFr by anti-EGFr MAbs.

The binding of ¹²⁵I-EGF (0.1 nM) to (A) A431 or (B) SW948 cells was determined in the presence of human (■, E7.6.3; ●, E2.5.1; ▲, E2.3.1; ▽, E7.5.2; ○, E7.8.2) or murine (▼, 225; ◆, 528) anti-EGFr antibodies, or in the presence of the human IgG2k control antibody (△,hIgG2k ). The binding of ¹²⁵I-EGF to the cells in the absence of antibodies was designated as 100%.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.

Figure 2 The inhibition of EGF-induced tyrosine phosphorylation of EGFr by E7.6.3 MAb.

While E7.6.3 did not activate the receptor tyrosine kinase activity, the antibody blocked EGF-triggered EGFr tyrosine phosphorylation in a dose-dependent manner, with a nearly complete inhibition at a concentration of 133 nM.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.

Figure 3 The inhibition of EGF-mediated cell activation by anti-EGFr antibodies.

The concurrent addition of E7.6.3 resulted in a dose-dependent inhibition of EGF-mediated extracellular acidification, whereas no effect was detected with the isotype-matched control antibody PK16.3.1.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.

Figure 4 The inhibition of in vitro tumor cell proliferation by anti-EGFr antibodies.

E7.6.3 inhibited the growth of A431 cells in a dose-dependent manner, with a maximal inhibition of 60%, a similar level of growth inhibition by E7.6.3 was observed with MDA-MB-468 cells.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.

Figure 5 The eradication of established A431 tumor xenografts by E7.6.3 MAb.

A431 cells were injected s.c. into nude mice on day 0. A, at day 7, mice were randomly divided into treatment groups (n=5) and were injected i.p. with PBS (○) or with 1 mg of either E7.6.3 (◆) or the control human myeloma IgG2k (■) antibody twice a week for 3 weeks. B, when the mean tumor sizes reached 0.13 (▲), 0.56 (▼), 0.73 (◆), or 1.2 (●) cm3, mice (n= 10)were treated with 1 mg E7.6.3 twice a week for 3 weeks. Control mice (○, n=10)received no treatment. C, at day 10, when tumor sizes reached 0.15 cm3 , mice (n=8) were injected i.p. with 200 μg (▲) or 50 μg (■) doses of E7.6.3, or 200 μg (△) or 50 μg (□) doses of 225 MAbs, twice a week for 3 weeks. Control mice (○) received no treatment.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.

Figure 6 The effect of E7.6.3 MAb on the growth of established human tumor xenografts.

E7.6.3 was also shown to be efficacious in inhibiting the growth of the breast carcinoma MDA-MB-468 xenografts. A similar anti-tumor activity of E7.6.3 was observed when the antibody was given via different administration routes.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.

Figure 7 Histopathology of E7.6.3-treated A431 xenografts.

A, mice with established A431 xenografts were treated i.p. with 0.5 mg of E7.6.3 MAb twice a week for 3 weeks. On day 76 after tumor cells injection, tumor-like nodules were excised and examined histologically. B, histological analysis of A431 xenografts excised from an untreated mouse.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer research, 59(6), 1236-1243.